{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06469281",
            "orgStudyIdInfo": {
                "id": "27T51-01"
            },
            "organization": {
                "fullName": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers",
            "officialTitle": "A Phase 1a/1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-learn-if-a-mucin-protein-targeting-immune-cell-therapy-administered-alone-or-in-combination-is-safe-and-how-well-it-works-for-adult-participants-with-recurrent-or-treatment-resistant-ovarian-cancers"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-06-28",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-06-29",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-06",
            "studyFirstSubmitQcDate": "2024-06-19",
            "studyFirstPostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer.\n\nThis study has two (2) major parts:\n\nPhase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion part will be to test 27T51 at the established dose level(s) from the dose escalation part and may include other medications given in combination with 27T51.\n\nInformation collected from this study will help researchers understand more fully whether this immune cell therapy, also known as CAR T cell therapy, can be safely used to treat solid tumors such as ovarian cancer.",
            "detailedDescription": "Former Sponsor 2seventy bio"
        },
        "conditionsModule": {
            "conditions": [
                "Epithelial Ovarian Cancer",
                "Primary Peritoneal Carcinoma",
                "Fallopian Tube Cancer"
            ],
            "keywords": [
                "Ovarian Cancer",
                "CAR T",
                "Peritoneal",
                "Fallopian Tube",
                "MUC16",
                "Immunotherapy"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 90,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "27T51 monotherapy",
                    "interventionNames": [
                        "Other: 27T51"
                    ]
                },
                {
                    "label": "Dose Expansion - Arm A",
                    "type": "EXPERIMENTAL",
                    "description": "27T51 monotherapy",
                    "interventionNames": [
                        "Other: 27T51"
                    ]
                },
                {
                    "label": "Dose Expansion - Arm B",
                    "type": "EXPERIMENTAL",
                    "description": "27T51+Cemiplimab",
                    "interventionNames": [
                        "Other: 27T51",
                        "Drug: Cemiplimab"
                    ]
                },
                {
                    "label": "Dose Expansion - Arm C",
                    "type": "EXPERIMENTAL",
                    "description": "27T51+Cemiplimab+Bevacizumab",
                    "interventionNames": [
                        "Other: 27T51",
                        "Drug: Cemiplimab",
                        "Drug: Bevacizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "27T51",
                    "description": "Intravenous (IV) infusion",
                    "armGroupLabels": [
                        "Dose Escalation",
                        "Dose Expansion - Arm A",
                        "Dose Expansion - Arm B",
                        "Dose Expansion - Arm C"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cemiplimab",
                    "description": "IV infusion",
                    "armGroupLabels": [
                        "Dose Expansion - Arm B",
                        "Dose Expansion - Arm C"
                    ],
                    "otherNames": [
                        "Libtayo",
                        "REGN2810"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Bevacizumab",
                    "description": "IV Infusion",
                    "armGroupLabels": [
                        "Dose Expansion - Arm C"
                    ],
                    "otherNames": [
                        "Avastin",
                        "Mvasi",
                        "Vegzelma",
                        "Zirabe"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of treatment emergent adverse events (TEAEs)",
                    "description": "Part 1a",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Incidence of adverse events of special interest (AESIs)",
                    "description": "Part 1a",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Incidence of adverse events of dose limiting toxicities (DLTs)",
                    "description": "Part 1a",
                    "timeFrame": "Up to 18 months"
                },
                {
                    "measure": "Manufacturing feasibility of 27T51",
                    "description": "Phase 1a/1b Determination of the feasibility of manufacturing 27T51 is measured by the percent of leukapheresis products collected that are able to be manufactured and released for infusion.",
                    "timeFrame": "Up to 3 years"
                },
                {
                    "measure": "Overall response rate (ORR) as assessed by the investigator",
                    "description": "Phase 1b",
                    "timeFrame": "Up to 48 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "ORR as assessed by the investigator",
                    "description": "Phase 1a",
                    "timeFrame": "Up to 48 months"
                },
                {
                    "measure": "Duration of response (DoR)",
                    "description": "Phase 1a/1b",
                    "timeFrame": "Up to 48 months"
                },
                {
                    "measure": "Disease control rate (DCR)",
                    "description": "Phase 1a/1b",
                    "timeFrame": "Up to 48 months"
                },
                {
                    "measure": "Incidence of TEAEs",
                    "description": "Phase 1b",
                    "timeFrame": "Up to 48 months"
                },
                {
                    "measure": "Incidence of AESIs",
                    "description": "Phase 1b",
                    "timeFrame": "Up to 48 months"
                },
                {
                    "measure": "Incidence of DLTs",
                    "description": "Phase 1b - Arms B and C",
                    "timeFrame": "Up to 48 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status \u2264 1\n2. Histological diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer according to World of Health Organization (WHO) 2020 classification\n3. Recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer, as described in the protocol\n4. Serum cancer antigen (CA) 125 \u2265 2 \u00d7 upper limit of normal (ULN) as assessed at the local lab by a 510(k) cleared test at screening\n5. Participants must have at least 1 measurable tumor lesion as defined by the response evaluation criteria in solid tumors (RECIST) 1.1.\n6. Expected survival \u2265 3 months\n\nKey Exclusion Criteria:\n\n1. Inadequate cardiovascular, renal and hepatic function, as described in the protocol\n2. Absolute lymphocyte count (ALC) \\< 100 cells/\u03bcL at time of leukapheresis\n3. History of Grade \u2265 2 hemorrhage within 30 days, or inadequate coagulation parameters, as described in the protocol\n4. Known history or presence of clinically relevant central nervous system (CNS) pathology, as described in the protocol\n5. Ongoing or recent (within 2 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for immune related adverse events (AEs)\n6. Treatment with any cellular or gene therapy\n\nNote: Other protocol-defined Inclusion/Exclusion criteria apply",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials Administrator",
                    "role": "CONTACT",
                    "phone": "844-734-6643",
                    "email": "clinicaltrials@regeneron.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trial Management",
                    "affiliation": "Regeneron Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "John Theurer Cancer Center Hackensack University Medical Center",
                    "city": "Hackensack",
                    "state": "New Jersey",
                    "zip": "07601",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Suzanne Kosky",
                            "role": "CONTACT",
                            "phone": "551-996-3986",
                            "email": "Suzanne.Kosky@hmhn.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.88593,
                        "lon": -74.04347
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",
            "accessCriteria": "Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010051",
                    "term": "Ovarian Neoplasms"
                },
                {
                    "id": "D000077216",
                    "term": "Carcinoma, Ovarian Epithelial"
                },
                {
                    "id": "D000005185",
                    "term": "Fallopian Tube Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004701",
                    "term": "Endocrine Gland Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000010049",
                    "term": "Ovarian Diseases"
                },
                {
                    "id": "D000000291",
                    "term": "Adnexal Diseases"
                },
                {
                    "id": "D000005831",
                    "term": "Genital Diseases, Female"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000005833",
                    "term": "Genital Neoplasms, Female"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000006058",
                    "term": "Gonadal Disorders"
                },
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000005184",
                    "term": "Fallopian Tube Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8328",
                    "name": "Fallopian Tube Neoplasms",
                    "asFound": "Fallopian Tube Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7863",
                    "name": "Endocrine Gland Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12972",
                    "name": "Ovarian Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3643",
                    "name": "Adnexal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8943",
                    "name": "Genital Diseases, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8945",
                    "name": "Genital Neoplasms, Female",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9163",
                    "name": "Gonadal Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M8327",
                    "name": "Fallopian Tube Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2189",
                    "name": "Fallopian Tube Cancer",
                    "asFound": "Fallopian Tube Cancer",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068258",
                    "term": "Bevacizumab"
                },
                {
                    "id": "C000627974",
                    "term": "Cemiplimab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000020533",
                    "term": "Angiogenesis Inhibitors"
                },
                {
                    "id": "D000043924",
                    "term": "Angiogenesis Modulating Agents"
                },
                {
                    "id": "D000006133",
                    "term": "Growth Substances"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000006131",
                    "term": "Growth Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M302522",
                    "name": "Cemiplimab",
                    "asFound": "RAD",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M246",
                    "name": "Bevacizumab",
                    "asFound": "Non-",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M22318",
                    "name": "Angiogenesis Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M9231",
                    "name": "Growth Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}